SILVER SPRING, Maryland, June 30, 2026
The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory T-cell (Treg) therapy designed to improve chronic graft-versus-host disease (GVHD)-free survival in adults with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Developed by Orca Biosystems, the groundbreaking cell-based immunotherapy introduces a new treatment approach that not only supports successful stem cell transplantation but also significantly reduces the risk of chronic GVHD, one of the most serious and life-altering complications affecting transplant recipients. The approval represents a major advancement in cellular immunotherapy, addressing an important unmet medical need for patients with high-risk blood cancers, including acute leukemia and myelodysplastic syndrome (MDS). By harnessing specialized donor-derived immune cells, Tregzi is designed to restore immune balance while preserving the anti-cancer effects of stem cell transplantation, potentially improving both long-term survival and quality of life for transplant patients.
First Regulatory T-Cell Therapy Redefines Stem Cell Transplantation
Tregzi is the first regulatory T-cell (Treg)-based immunotherapy approved by the FDA and introduces an innovative strategy for immune system reconstruction following stem cell transplantation. The therapy is manufactured using donor-derived hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcons) collected from the peripheral blood of an 8/8 HLA-matched related or unrelated donor. Following chemotherapy conditioning, patients receive Tregzi to rebuild healthy blood-forming and immune systems while reducing the likelihood that transplanted donor immune cells will attack healthy tissues, the underlying cause of chronic graft-versus-host disease.
Unlike conventional transplantation approaches that primarily focus on eliminating cancer, Tregzi actively promotes immune tolerance, helping regulate immune responses without compromising the transplant’s anti-leukemia activity. This novel mechanism represents a significant advancement in allogeneic cell therapy, highlighting the growing role of precision immunology in improving transplant outcomes for patients with aggressive hematologic malignancies.
PRECISION-T Trial Demonstrates Significant Clinical Benefit
Advertisement
The FDA based its approval on findings from the Phase 3 PRECISION-T clinical trial, which enrolled 187 adult patients with blood cancers undergoing allogeneic stem cell transplantation. Participants were randomly assigned to receive either Tregzi or a conventional stem cell transplant, with the primary endpoint measuring chronic GVHD-free survival over a two-year period. The study produced highly compelling results, with 78% of patients receiving Tregzi remaining free from moderate or severe chronic GVHD at one year, compared with only 38.4% of patients receiving standard transplantation.
After adjusting for death as a competing risk, only 12.6% of patients treated with Tregzi developed serious chronic GVHD within one year versus 44% in the standard transplant group, demonstrating a substantial reduction in one of transplantation’s most devastating complications. Safety findings were also encouraging, with adverse events remaining consistent with those commonly observed following stem cell transplantation. No severe infusion reactions or graft failure were reported during the study, reinforcing the therapy’s favorable clinical profile. Based on these results, the FDA concluded that the benefits of Tregzi outweigh its risks, supporting approval for eligible adult patients.
Approval Advances the Future of Cellular Immunotherapy
The approval of Tregzi marks an important milestone in the evolution of advanced cellular therapies for hematologic cancers and stem cell transplantation. Recognizing its potential to address a serious unmet medical need, the therapy received both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation, facilitating its regulatory development. The approval further highlights the FDA’s continued commitment to accelerating innovative therapies capable of improving patient outcomes in life-threatening diseases.
For patients requiring allogeneic stem cell transplantation, preventing chronic graft-versus-host disease is often as critical as achieving cancer remission because the condition can significantly impair long-term survival, organ function, and quality of life. By combining donor stem cells with specialized immune-regulating T cells, Tregzi introduces a first-in-class therapeutic approach that redefines transplant medicine through immune tolerance rather than conventional immune suppression. As cell-based immunotherapies continue to transform oncology and regenerative medicine, the approval of Tregzi establishes a new benchmark for innovation in blood cancer treatment and opens the door for future advances in precision immune cell therapies.
Source: FDA press release
